Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press44510.17650/2313-805X-2022-9-2-111-119RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИAntitumor effect of recombinant interferon-gamma in an experimental model of Ehrlich’s bilateral solid carcinomaПротивоопухолевый эффект рекомбинантного интерферона гамма в экспериментальной модели билатеральной солидной карциномы Эрлихаhttps://orcid.org/0000-0003-0599-0691IsaevaV. G.ИсаеваВ. Г.
Russian Federation

10 Marshala Zhukova St., Obninsk 249036

249036 Обнинск, ул. Маршала Жукова, 10

https://orcid.org/0000-0001-9103-9688GrivtsovaL. Y.ГривцоваЛ. Ю.
Russian Federation

10 Marshala Zhukova St., Obninsk 249036

249036 Обнинск, ул. Маршала Жукова, 10

https://orcid.org/0000-0002-2166-6608ZhovtunL. P.ЖовтунЛ. П.
Russian Federation

10 Marshala Zhukova St., Obninsk 249036

249036 Обнинск, ул. Маршала Жукова, 10

https://orcid.org/0000-0003-3095-4158SamborskyS. M.СамборскийС. М.
Russian Federation

Stanislav Mikhailovich Samborsky

10 Marshala Zhukova St., Obninsk 249036

Станислав Михайлович Самборский

249036 Обнинск, ул. Маршала Жукова, 10

samborsky.stas@yandex.ruhttps://orcid.org/0000-0002-0023-4216FalaleevaN. A.ФалалееваН. А.
Russian Federation

10 Marshala Zhukova St., Obninsk 249036

249036 Обнинск, ул. Маршала Жукова, 10

A. F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России15052022921111192606202226062022Copyright ©; 2022, Isaeva V.G., Grivtsova L.Y., Zhovtun L.P., Samborsky S.M., Falaleeva N.A.Copyright ©; 2022, Исаева В.Г., Гривцова Л.Ю., Жовтун Л.П., Самборский С.М., Фалалеева Н.А.2022Isaeva V.G., Grivtsova L.Y., Zhovtun L.P., Samborsky S.M., Falaleeva N.A.Исаева В.Г., Гривцова Л.Ю., Жовтун Л.П., Самборский С.М., Фалалеева Н.А.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/445

Introduction. Immunotherapy, which is part of the complex and combined cancer therapy, is one of the priority areas in the treatment of cancer patients. However, the effectiveness of the use of immunotherapeutic drugs of the latest generation is not so high, and in some patients the effect of therapy was short-lived. Factors that prevent the full realization of the antitumor effect of cytostatics and immunopreparations may be the features of the antigenic composition of the tumor, as well as its cellular and stromal microenvironment. These facts contributed to the development of a new strategy, designated as immunoredaction of cancer by exposure to various biologically active agents that can change the body – tumor ratio in favor of the patient and make the tumor available for the implementation of antitumor effects of the host immune system.

The study objective – experimental substantiation of the development of new immunotherapeutic approaches in the treatment of aggressive forms of cancer.

Materials and methods. An experimental study of the effect of human recombinant interferon-gamma (IFNγ) on the growth of Ehrlich’s carcinoma during subcutaneous bilateral transplantation of tumor cells to animals was carried out. Transplantation of Ehrlich’s carcinoma to male F1 hybrids (SWAhC57Bl6) was performed by subcutaneous injection of 2.0 × 106 tumor cells (7‑day culture) in 0.1 ml of suspension into the lateral surface of the right and left femur with imitation of multicentric growth.

Results. A day after the course of drug administration (day 6 of tumor node growth), the effect of suppressing tumor growth in relation to growth in the control group was noted. The maximum inhibition effect of 19.8 % (p <0.05) of tumor growth was obtained 5 days after the course of the drug (10 days of tumor growth, right node) and 18.5 % (p <0.001) 9 days after administration (14 days of tumor growth, left node).

Conclusion. Thus, a distinct, statistically significant antitumor effect of IFNγ was established in relation to a tumor with a multicentric growth pattern.

Введение. Иммунотерапия, входящая в состав комплексной и комбинированной терапии рака, является одним из приоритетных направлений в лечении онкологических больных. Однако эффективность применения иммунотерапевтических препаратов последнего поколения не так высока, а у некоторых больных эффект терапии оказался кратковременным. Факторами, препятствующими полноценной реализации противоопухолевого эффекта цитостатиков и иммунопрепаратов, возможно, являются особенности антигенного состава опухоли, а также ее клеточного и стромального микроокружения. Данные факты способствовали развитию новой стратегии, обозначенной как иммуноредактирование рака посредством воздействия различных биологически активных агентов, способных изменить соотношение организм – опухоль в пользу больного и сделать опухоль доступной для реализации противоопухолевого воздействия иммунной системы хозяина.

Цель исследования – экспериментальное обоснование разработки новых иммунотерапевтических подходов в лечении агрессивных форм рака.

Материалы и методы. Проведено экспериментальное изучение влияния человеческого рекомбинантного интерферона гамма (IFNγ) на рост карциномы Эрлиха при подкожной билатеральной трансплантации клеток опухоли животным. Трансплантацию карциномы Эрлиха мышам-самцам гибридам F1 (СВАхС57Вl6) проводили подкожным  введением 2,0 × 106 опухолевых клеток (7‑дневная культура) в 0,1 мл суспензии в область латеральной поверхности правого и левого бедер с имитацией мультицентричного роста.

Результаты. Через сутки после курса введения препарата (6‑е сутки роста опухолевых узлов) отмечен эффект подавления роста опухоли по отношению к росту в контрольной группе. Максимальный эффект торможения, составляющий 19,8 % (р <0,05) роста опухоли, получен через 5 сут после курса препарата (10‑е сутки опухолевого роста, правый узел) и 18,5 % (р <0,001) через 9 суток после введения (14‑е сутки опухолевого роста, левый узел).

Заключение. Таким образом, установлен отчетливый, статистически значимый противоопухолевый эффект IFNγ в отношении опухоли с мультицентричным характером роста.

immunotherapycytokinesinterferon-gammatumors with multicentric growth patternиммунотерапияцитокиныинтерферон гаммаопухоли с мультицентричным характером ростаTian T., Olson S., Whitacre J.M., Harding A. et al. The origins of cancer robustness and evolvability. Integr Biol (Camb.) 2011;3(1):17–30. DOI: 10.1039/c0ib00046a.Dunn G.P., Koebel C.M., Schreiber R.D. et al. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6(11):836–48. DOI: 10.1038/nri1961.Manguso R.T., Pope H.W., Zimmer M.D. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 2017;547(7664):413–8. DOI: 10.1038/nature23270.Kasahara T., Hooks J.J., Dougherty S.F. et al. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol 1983;130(4):1784–9.Corthay A., Skovseth D.K., Lundin K.U. et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005;22(3):371–83. DOI: 10.1016/j.immuni.2005.02.003.Matsushita H., Hosoi A., Ueha S. et al. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN gamma-dependent cell-cycle arrest. Cancer Immunol Res 2015;3(1):26–36. DOI: 10.1158/2326-6066.CIR-14-0098.Girardi M., Oppenheim D.E., Steele C.R. et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294(5542):605–9. DOI: 10.1126/science.1063916.Gao Y., Yang W., Pan M. et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003;198(3):433–42. DOI: 10.1084/jem.20030584.Ribot J.C., deBarros A., Pang D.J. et al. CD27 is a thymic determinant of the balance between interferon-gammaand interleukin 17-producing gamma-delta T cell subsets. Nat Immunol 2009; 10(4):427–36. DOI: 10.1038/ni.1717.Silva-Santos B., Serre K., Norell H. γδ T cells in cancer. Nat Rev Immunol 2015;15(11):683–91. DOI: 10.1038/nri3904.Yu J., Wei M., Becknell B. et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 2006;24(5):575–90. DOI: 10.1016/j.immuni.2006.03.016.Keppel M.P., Saucier N., Mah A.Y. et al. Activation-specific metabolic requirements for NK cell IFN-gamma production. J Immunol 2015;194(4):1954–62. DOI: 10.4049/jimmunol.1402099.Yoshimoto T., Takeda K., Tanaka T. et al. IL-12 up-regulates IL-18 receptor B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998;161(7):3400–7.Barr T.A., Brown S., Mastroeni P. et al. TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J Immunol 2010;185(5):2783–9. DOI: 10.4049/jimmunol.1001431.Bao Y., Liu X., Han C. et al. Identification of IFN-gamma-producing innate B cells. Cell Res 2014;24(2):161–76. DOI: 10.1038/cr.2013.155.Ohteki T., Fukao T., Suzue K. et al. Interleukin 12-dependent interferon gamma production by CD8 alpha+ lymphoid dendritic cells. J Exp Med 1999;189(12):1981–6. DOI: 10.1084/jem.189.12.1981.Nguyen K.B., Cousens L.P., Doughty L.A. et al. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000;1(1):70–6. DOI: 10.1038/76940.Matikainen S., Paananen A., Miettinen M. et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 2001;31(7):2236–45.De Veer M.J., Holko M., Frevel M. et al. Functional classification of interferonstimulated genes identified using microarrays. J Leukoc Biol 2001;69(6):912–20.Shankaran V., Ikeda H., Bruce A.T. et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410(6832):1107–11. DOI: 10.1038/35074122.Wang L., Wang Y., Song Z. et al. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res 2015;35(4):273–80. DOI: 10.1089/jir.2014.0132.Kaplan D.H., Shankaran V., Dighe A.S. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95(13):7556–61. DOI: 10.1073/pnas.95.13.7556.Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97(1):192–7. DOI: 10.1182/blood.v97.1.192.Street S.E., Trapani J.A., MacGregor D. et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196(1):129–34. DOI: 10.1084/jem.20020063.Enzler T., Gillessen S., Manis J.P. et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003;197(9):1213–9. DOI: 10.1084/jem.20021258.Mitra-Kaushik S., Harding J., Hess J. et al. Enhanced tumori-genesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood 2004;104(10):3305–11. DOI: 10.1182/blood-2004-01-0266.Anderson C.C., Bretscher P., Corthay A. et al. Immunological tolerance. Part I of a Report of a Workshop on foundational concepts of immune regulation. Scand J Immunol 2017;85(2):84–94. DOI: 10.1111/sji.12500.Girardi M., Glusac E., Filler R.B. et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003;198(5):747–55. DOI: 10.1084/jem.20021282.Tovey M.G., Streuli M., Gresser I. et al. Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc Natl Acad Sci USA 1987;84(14):5038–42. DOI: 10.1073/pnas.84.14.5038.Gattass C.R., King L.B., Luster A.D. et al. Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J Exp Med 1994;179(4): 1373–8. DOI: 10.1084/jem.179.4.1373.Sercan O., Hammerling G.J., Arnold B. et al. Innate immune cells contribute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell homeostasis. J Immunol 2006;176(2): 735–9. DOI: 10.4049/jimmunol.176.2.735.Baldridge M.T., King K.Y., Boles N.C. et al. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature 2010;465(7299):793–7. DOI: 10.1038/nature09135.Duque G., Huang D.C., Dion N. et al. Interferon γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res 2011;26(7):1472–83. DOI: 10.1002/jbmr.350.Wang F., Xu J., Zhu Q. et al. Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression. PLoS One 2013;8(11):e79064. DOI: 10.1371/journal.pone.0079064.Lv N., Gao Y., Guan H. et al. Inflammatory mediators, tumor necrosis factor-alpha and interferon-gamma, induce EMT in human PTC cell lines. Oncol Lett 2015;10(4):2591–7. DOI: 10.3892/ol.2015.3518.Lu Y., Gu X., Chen L. et al. Interferongamma produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells. Angiogenesis 2014;17(3):529–40. DOI: 10.1007/s10456-013-9397-y.Shime H., Maruyama A., Yoshida S. et al. Toll-like receptor 2 ligand and interferongamma suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. Oncoimmunology 2017;7(1):e1373231. DOI: 10.1080/2162402X.2017.1373231.Руководство по проведению доклинических исследований лекарственных веществ. Под ред. Р.У. Хабриева. М., 2005.Guidelines for conducting preclinical studies of medicinal substances. Ed. by R.U. Khabriev. Moscow, 2005. (In Russ.).Dighe A.S., Richards E., Old L.J. et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1(6):447–56. DOI: 10.1016/1074-7613(94)90087-6.Kaplan D.H., Shankaran V., Dighe A.S. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95(13):7556–61. DOI: 10.1073/pnas.95.13.7556.Wang Q.S., Shen S.Q., Sun H.W. et al. Interferon-gamma induces autophagyassociated apoptosis through induction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells. Biochem Biophys Res Commun 2018;498(4):1058–65. DOI: 10.1016/j.bbrc.2018.03.118.Zhang R., Banik N.L., Ray S.K. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma cells for induction of apoptosis. Neurochem Res 2007;32(12):2194–202. DOI: 10.1007/s11064-007-9417-7.Detjen K.M., Farwig K., Welzel M. et al. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 2001;49(2):251–62. DOI: 10.1136/gut.49.2.251.Schmitt M.J., Philippidou D., Reinsbach S.E. et al. Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal 2012;10(1):41. DOI: 10.1186/1478-811X-10-41.Enzler T., Gillessen S., Manis J.P. et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003;197(9):1213–9. DOI: 10.1084/jem.20021258.Braumüller H., Wieder T., Brenner E. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494(7437):361–5. DOI: 10.1038/nature11824.Zhang B., Karrison T., Rowley D.A. et al. IFNγ - and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008;118(4):1398–404. DOI: 10.1172/JCI33522.Listopad J., Kammertoens T., Anders K. et al. Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci USA 2013;110(6):2276–81. DOI: 10.1073/pnas.1218295110.Kammertoens T., Friese C., Arina A. et al. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature 2017;545(7652):98–102. DOI: 10.1038/nature22311.Windbichler G.H., Hausmaninger H., Stummvoll W. et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82(6):1138–44. DOI: 10.1054/bjoc.1999.1053.Marijt K.A., Sluijter M., Blijleven L. et al. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling. J Immunother Cancer 2019;7(1):152. DOI: 10.1186/s40425-019-0627-8.Morgado M., Sutton M.N., Simmons M. et al. Tumor necrosis factor-alpha and interferon-gamma stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFkappaB. Oncotarget 2016;7(12):14871–84. DOI: 10.18632/oncotarget.7652.